FDMT Form 4: CLO sells 2,408 shares at $10 under 10b5-1

4D Molecular Therapeutics (FDMT) reported an insider transaction on a Form 4.

Rhea-AI Filing Summary

4D Molecular Therapeutics (FDMT) reported an insider transaction on a Form 4. The company’s Chief Legal Officer sold 2,408 shares of common stock at $10 on October 9, 2025, pursuant to a Rule 10b5-1 trading plan adopted on June 6, 2025.

Following the sale, the reporting person beneficially owned 5,188 shares, held directly. The filing was made by one reporting person.

Insights

Governance & Insider Trading Analyst

Routine 10b5-1 insider sale disclosed; neutral signal.

The filing lists a sale of 2,408 common shares at $10 on 10/09/2025 by the company’s Chief Legal Officer. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 6, 2025, indicating an automated schedule.

After this trade, direct beneficial ownership stands at 5,188 shares. Form 4 disclosures like this are standard and do not, by themselves, indicate a change in business performance or outlook.

Insider Trade Summary

Net Seller: 2,408 shares

Net Sell 1 txn

Insider Bizily Scott

Role Chief Legal Officer

Sold 2,408 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,408	$10.00	$24K

Holdings After Transaction: Common Stock — 5,188 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FDMT disclose in this Form 4 filing?

A Chief Legal Officer sold 2,408 shares of common stock at $10 on October 9, 2025 under a Rule 10b5-1 plan.

How many FDMT shares did the insider sell and at what price?

The insider sold 2,408 shares at $10 per share.

How many FDMT shares does the insider hold after the transaction?

After the sale, the insider beneficially owned 5,188 shares.

When was the trading plan for this FDMT transaction adopted?

The Rule 10b5-1 trading plan was adopted on June 6, 2025.

What is the insider’s role at FDMT?

The reporting person is FDMT’s Chief Legal Officer.

Was the ownership reported as direct or indirect?

The ownership reported following the transaction was direct.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/14/2025 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bizily Scott

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/09/2025		S(1)		2,408	D	$10	5,188	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

	/s/ Scott Bizily	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.